Firstpost
  • Home
  • Video Shows
    Vantage Firstpost America Firstpost Africa First Sports
  • World
    US News
  • Explainers
  • News
    India Opinion Cricket Tech Entertainment Sports Health Photostories
  • Asia Cup 2025
Apple Incorporated Modi ji Justin Trudeau Trending

Sections

  • Home
  • Live TV
  • Videos
  • Shows
  • World
  • India
  • Explainers
  • Opinion
  • Sports
  • Cricket
  • Health
  • Tech/Auto
  • Entertainment
  • Web Stories
  • Business
  • Impact Shorts

Shows

  • Vantage
  • Firstpost America
  • Firstpost Africa
  • First Sports
  • Fast and Factual
  • Between The Lines
  • Flashback
  • Live TV

Events

  • Raisina Dialogue
  • Independence Day
  • Champions Trophy
  • Delhi Elections 2025
  • Budget 2025
  • US Elections 2024
  • Firstpost Defence Summit
Trending:
  • PM Modi in Manipur
  • Charlie Kirk killer
  • Sushila Karki
  • IND vs PAK
  • India-US ties
  • New human organ
  • Downton Abbey: The Grand Finale Movie Review
fp-logo
No trouble for Mohali unit, claims Ranbaxy; but what about governance?
Whatsapp Facebook Twitter
Whatsapp Facebook Twitter
Apple Incorporated Modi ji Justin Trudeau Trending

Sections

  • Home
  • Live TV
  • Videos
  • Shows
  • World
  • India
  • Explainers
  • Opinion
  • Sports
  • Cricket
  • Health
  • Tech/Auto
  • Entertainment
  • Web Stories
  • Business
  • Impact Shorts

Shows

  • Vantage
  • Firstpost America
  • Firstpost Africa
  • First Sports
  • Fast and Factual
  • Between The Lines
  • Flashback
  • Live TV

Events

  • Raisina Dialogue
  • Independence Day
  • Champions Trophy
  • Delhi Elections 2025
  • Budget 2025
  • US Elections 2024
  • Firstpost Defence Summit
  • Home
  • Business
  • No trouble for Mohali unit, claims Ranbaxy; but what about governance?

No trouble for Mohali unit, claims Ranbaxy; but what about governance?

FP Editors • December 20, 2014, 22:03:11 IST
Whatsapp Facebook Twitter

What Ranbaxy need to understand is that, whether legally required or not, it is better to make such disclosures, which will increase transparency and boost the company’s image

Advertisement
Subscribe Join Us
Add as a preferred source on Google
Prefer
Firstpost
On
Google
No trouble for Mohali unit, claims Ranbaxy; but what about governance?

Ranbaxy Laboratories, after getting hammered by investors for a day, has clarified its Mohali unit is not in trouble and that it stopped supply of atorvastatin, or Lipitor, to the US markets from the unit purely for commercial reasons.

The company’s shares had hit a 52-week low yesterday, after the Business Standard reported the unit has been issued the Form 483 by the US FDA indicating the manufacturing practice at the unit does not conform to its rules.

STORY CONTINUES BELOW THIS AD

The report also said the company has not yet resumed supply to the US of its cholestrol lowering generic Lipitor from the unit.

“We will resume supplies of atorvastatin for US pharmacies and retail market, manufactured at the Mohali facility over the next few months,” Ranbaxy CEO and MD Arun Sawhney has been quoted as saying in a report in the Times of India today.

More from Business
Hyundai India’s Rs 27,870 crore IPO oversubscribed by 2.28X, largely driven by institutional investors Hyundai India’s Rs 27,870 crore IPO oversubscribed by 2.28X, largely driven by institutional investors How Indian fintech startups are driving Malaysia’s UPI-like digital payments revolution How Indian fintech startups are driving Malaysia’s UPI-like digital payments revolution

[caption id=“attachment_903095” align=“alignleft” width=“380”]Reuters Reuters[/caption]

The company’s Lipitor had 55 percent market share in the US which significantly eroded late last year, after the company voluntarily recalled 41 lots of 10 mg, 20 mg and 40 mg tablets on suspicion that they contain very small glass particles.

In a bid to reinforce investor confidence, Sawhney has also said the US FDA has not conducted any inspection of the unit this year.

About receiving the Form 483 from the US FDA, he downplayed it saying they were just the regulator’s observations about manufacturing at the unit and has no impact on regulatory filings from the unit.

Impact Shorts

More Shorts
Chennai Ranks #1 in Challan Checks: ACKO Insights for Smarter Car and Two Wheeler Insurance Decisions

Chennai Ranks #1 in Challan Checks: ACKO Insights for Smarter Car and Two Wheeler Insurance Decisions

Tata Harrier EV vs Mahindra XEV 9e: Design and road presence compared

Tata Harrier EV vs Mahindra XEV 9e: Design and road presence compared

However, the issue has brought into focus the shoddy corporate governance at the company. According to the BS report, the Form 483 was issued to the unit a few months ago. However, the company has not make any disclosure about this till date.

The reason for this, according to Amit Chander, partner, Baring Private Equity, quoted in the BS report, is that it is not mandatory for companies in India to disclose the receipt of the Form 483.

STORY CONTINUES BELOW THIS AD

So, it is easy going for the companies. They can hold back the sensitive information as long as they want to. That is what Ranbaxy did.

So technically, the company cannot be blamed. But just adhering to laws does not mean good corporate governance. That is the reason analysts are bothered. According to the ToI report, they have raised concerns saying Ranbaxy should have made necessary disclosures much earlier.

What Ranbaxy need to understand is that, whether legally required or not, it is better to make such disclosures, which will increase transparency and boost the company’s image. For Ranbaxy, which is under intense scrutiny after its run-ins with US FDA, this is of utmost importance now.

Tags
India Corporate governance Drugs CompanyWatch Ranbaxy Healthcare Lipitor
End of Article
Latest News
Find us on YouTube
Subscribe
End of Article

Impact Shorts

Chennai Ranks #1 in Challan Checks: ACKO Insights for Smarter Car and Two Wheeler Insurance Decisions

Chennai Ranks #1 in Challan Checks: ACKO Insights for Smarter Car and Two Wheeler Insurance Decisions

Chennai leads India in challan checks, with drivers checking their e-challans over 5 times a month on average. Helmet non-compliance is the most broken rule, accounting for 34.8% of all traffic offences in Chennai. Regular digital challan checks help drivers avoid hefty fines, promote safe driving, and improve insurance premiums.

More Impact Shorts

Top Stories

Russian drones over Poland: Trump’s tepid reaction a wake-up call for Nato?

Russian drones over Poland: Trump’s tepid reaction a wake-up call for Nato?

As Russia pushes east, Ukraine faces mounting pressure to defend its heartland

As Russia pushes east, Ukraine faces mounting pressure to defend its heartland

Why Mossad was not on board with Israel’s strike on Hamas in Qatar

Why Mossad was not on board with Israel’s strike on Hamas in Qatar

Turkey: Erdogan's police arrest opposition mayor Hasan Mutlu, dozens officials in corruption probe

Turkey: Erdogan's police arrest opposition mayor Hasan Mutlu, dozens officials in corruption probe

Russian drones over Poland: Trump’s tepid reaction a wake-up call for Nato?

Russian drones over Poland: Trump’s tepid reaction a wake-up call for Nato?

As Russia pushes east, Ukraine faces mounting pressure to defend its heartland

As Russia pushes east, Ukraine faces mounting pressure to defend its heartland

Why Mossad was not on board with Israel’s strike on Hamas in Qatar

Why Mossad was not on board with Israel’s strike on Hamas in Qatar

Turkey: Erdogan's police arrest opposition mayor Hasan Mutlu, dozens officials in corruption probe

Turkey: Erdogan's police arrest opposition mayor Hasan Mutlu, dozens officials in corruption probe

Top Shows

Vantage Firstpost America Firstpost Africa First Sports
Latest News About Firstpost
Most Searched Categories
  • Web Stories
  • World
  • India
  • Explainers
  • Opinion
  • Sports
  • Cricket
  • Tech/Auto
  • Entertainment
  • IPL 2025
NETWORK18 SITES
  • News18
  • Money Control
  • CNBC TV18
  • Forbes India
  • Advertise with us
  • Sitemap
Firstpost Logo

is on YouTube

Subscribe Now

Copyright @ 2024. Firstpost - All Rights Reserved

About Us Contact Us Privacy Policy Cookie Policy Terms Of Use
Home Video Shorts Live TV